Barclays Boosts Teladoc Health (NYSE:TDOC) Price Target to $29.00
Teladoc Health (NYSE:TDOC – Get Rating) had its price target increased by Barclays from $28.00 to $29.00 in a research note released on Thursday, The Fly reports.
Several other brokerages also recently issued reports on TDOC. SVB Leerink upgraded Teladoc Health from a market perform rating to an outperform rating and set a $34.00 price target for the company in a report on Thursday, February 23rd. Canaccord Genuity Group cut their price target on shares of Teladoc Health from $40.00 to $36.00 and set a buy rating on the stock in a research note on Monday, March 6th. Credit Suisse Group dropped their price objective on shares of Teladoc Health from $30.00 to $27.00 and set a neutral rating on the stock in a report on Friday, March 10th. SVB Securities upgraded shares of Teladoc Health from a market perform rating to an outperform rating and set a $34.00 price objective on the stock in a report on Thursday, February 23rd. Finally, Stephens started coverage on Teladoc Health in a report on Tuesday, April 11th. They set an equal weight rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $32.78.
Teladoc Health Stock Down 3.2 %
Shares of NYSE TDOC opened at $26.53 on Thursday. The firm has a 50 day moving average price of $25.99 and a 200 day moving average price of $26.84. The stock has a market cap of $4.31 billion, a P/E ratio of -0.61 and a beta of 1.08. Teladoc Health has a 52-week low of $21.60 and a 52-week high of $44.66. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.15 and a current ratio of 3.29.
Teladoc Health (NYSE:TDOC – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The health services provider reported earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. The company had revenue of $637.71 million for the quarter, compared to analysts’ expectations of $633.71 million. Teladoc Health had a negative net margin of 285.51% and a negative return on equity of 5.05%. Analysts expect that Teladoc Health will post -1.51 EPS for the current year.
Insider Activity at Teladoc Health
In other Teladoc Health news, CMO Stephany Verstraete sold 2,254 shares of the company’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $25.36, for a total value of $57,161.44. Following the transaction, the chief marketing officer now directly owns 35,188 shares in the company, valued at $892,367.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction that occurred on Friday, February 17th. The stock was sold at an average price of $30.21, for a total transaction of $30,210.00. Following the transaction, the senior vice president now owns 20,408 shares in the company, valued at $616,525.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CMO Stephany Verstraete sold 2,254 shares of the company’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $25.36, for a total value of $57,161.44. Following the completion of the transaction, the chief marketing officer now directly owns 35,188 shares in the company, valued at $892,367.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,301 shares of company stock worth $1,180,135. Company insiders own 1.55% of the company’s stock.
Institutional Investors Weigh In On Teladoc Health
Institutional investors have recently modified their holdings of the business. ARK Investment Management LLC raised its stake in Teladoc Health by 8.7% in the 1st quarter. ARK Investment Management LLC now owns 20,584,180 shares of the health services provider’s stock worth $533,130,000 after purchasing an additional 1,655,740 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Teladoc Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 13,639,307 shares of the health services provider’s stock worth $345,757,000 after purchasing an additional 78,859 shares during the period. The State of Michigan Retirement System increased its holdings in shares of Teladoc Health by 1.3% during the first quarter. The State of Michigan Retirement System now owns 3,833,000 shares of the health services provider’s stock worth $99,275,000 after purchasing an additional 50,000 shares during the period. Geode Capital Management LLC grew its position in Teladoc Health by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,169,548 shares of the health services provider’s stock worth $51,309,000 after buying an additional 72,396 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Teladoc Health by 5.4% during the fourth quarter. Two Sigma Investments LP now owns 1,892,357 shares of the health services provider’s stock worth $44,754,000 after buying an additional 97,111 shares in the last quarter. Institutional investors own 84.14% of the company’s stock.
Teladoc Health Company Profile
(Get Rating)
Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services.
Featured Articles
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.
